louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02455466: Altered PSA Test Due to Possible Suspected Heterophilic Antibodies
Official title: Altered PSA Test Due to Possible Suspected Heterophilic Antibodies
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: PSA
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2015-05-27
Enrollment: 50
Sex: MALE
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male, where a PSA measurement is planned

Brief summary: The purpose of this study is to investigate if clinically non explainable high or low Prostate-specific antigen (PSA) levels are associated with heterophilic antibodies in the serum of participants. The investigators will examine if heterophilic antibodies are the reasons of altered PSA levels.


Eligibility criteria: Inclusion Criteria:

* Male, with a a clinically high or low unexplainable PSA measurement
* Age between 40 and 90 years
* Written informed consent

Exclusion Criteria:

* Female
* No PSA measurement available or planned
* Age over 90 or under 40 years

Primary outcomes:
measure: Presence of heterophilic antibodies in the serum of participants
timeFrame: 1.5 years
measure: Altered PSA levels due to the Presence of Heterophilic antibodies
timeFrame: 1.5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: University Hospital Zürich
Study officials:
References:
Clinical trial NCT06797466: Three Dimensional Virtual Reconstruction (3D) in Percutaneous Nephrolithotomy
Official title: Investigation of the Effect of Three Dimensional Virtual Reconstruction (3D) on Percutaneous Nephrolithotomy Learning Curve in Specialist Training
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: PNL
Stone, Kidney
Lead sponsor: Adiyaman University
Sponsor class: OTHER
First posted: 2025-01-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of our study is to investigate the effect of 3D imaging technique on the PCNL learning curve in specialist training.


Eligibility criteria: Inclusion Criteria:

* Patients with kidney stones larger than 2 cm and those with PCNL indication.

Exclusion Criteria:

* Patients with missing CT images, missing clinical information, or inaccessible

Primary outcomes:
measure: Number of Participants with perioperative Bleeding.
timeFrame: immediately after the intervention/procedure/surgery
measure: Number of Participants with stone free
timeFrame: 1 month after the intervention/procedure/surgery
measure: leng of the hospital stay
timeFrame: immediately after the intervention/procedure/surgery
Secondary outcomes:
measure: Number of Participants with Complication
timeFrame: immediately after the intervention/procedure/surgery
Other outcomes:
Locations:
city: Adıyaman
country: Turkey
facility: Adıyaman University
Study officials:
References:
Clinical trial NCT00417066: Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
Official title: The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Premature Ovarian Failure
Keywords: poor responders
GnRH antagonist
GnRH agonist
flare up
short protocol
Lead sponsor: Eugonia
Sponsor class: OTHER
First posted: 2006-12-29
Enrollment: 270
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare ovulation induction using a flexible GnRH antagonist protocol and flare up GnRH agonist protocol in IVF patients with poor response to ovarian stimulation. Our hypothesis is that the antagonist protocol provides better IVF outcomes compared to the flare up protocol in this group of patients.

Detailed description: Poor responders are women who fail to respond effectively to the usual gonadotropin stimulation protocol applied in an IVF cycle. It seems that a diminished ovarian reserve is the principal factor of poor ovarian response. Several strategies have been proposed for the management of poor responders, including flare up GnRH agonist regimens and the GnRH antagonist, which presents a new hope in this group of patients.

Comparisons: Poor responder patients (see inclusion criteria) commencing an IVF treatment cyle will receive ovarian stimulation treatment either using a GnRH antagonist (Ganirelix) or flare up agonist (Arvekap) protocol. Primary outcomes compared will be ongoing pregnancy rates in the two treatment groups.

Eligibility criteria: Inclusion Criteria:

* regular menstrual cycle
* 1 or more failed IVF attempts with poor response
* 5 or fewer oocytes retrieved
* FSH\>12 IU/l on day 3

Exclusion Criteria:

* PCOS
* Normal responders

Primary outcomes:
measure: Ongoing pregnancy rate per embryo transfer
Secondary outcomes:
measure: Duration of ovarian stimulation, total rFSH used, estradiol, LH and progesterone concentration on hCG day.
measure: Number of mature oocytes retrieved.
measure: Number of fertilised oocytes.
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Eugonia
Study officials:
affiliation: Eugonia
name: Tryfon Lainas, PhD
role: STUDY_DIRECTOR
References:
citation: Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003 Jan-Feb;9(1):61-76. doi: 10.1093/humupd/dmg007.
citation: Lainas TG, Sfontouris IA, Papanikolaou EG, Zorzovilis JZ, Petsas GK, Lainas GT, Kolibianakis EM. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Hum Reprod. 2008 Jun;23(6):1355-8. doi: 10.1093/humrep/den107. Epub 2008 Apr 10.
Clinical trial NCT06066866: Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment
Official title: Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Healthy
IBS - Irritable Bowel Syndrome
Inflammatory Bowel Diseases
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2023-10-04
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care

Brief summary: GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.

Detailed description: Current guidelines (AGA Clinical Practice Update, 2020) report the definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. To date, there is unlimited knowledge regarding the diagnostic criterion which has been limited by nonspecific and nonsensitive testing such as breath tests. Breath tests have a limited use in patients with IBS-D who inherently have increased gut transit time rendering the testing invalid for accurately measuring small intestinal bacteria. Additionally, the relationship between SIBO and symptoms in patients without obvious risk factors (such as anatomical changes due to surgery) is unknown. The investigators study aims to investigate the microbial landscape of the small intestine in healthy patients and those with GI disease (suspected or diagnosed) undergoing an upper endoscopy by collecting an aspirate of patient small intestinal fluid and studying it.

Eligibility criteria: Inclusion Criteria:

* Age \>18years
* Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care

Exclusion Criteria:

Children (under age 18years) Pregnant Women and Fetuses Neonates (0 - 28 days) Impaired Decision Making Capacity

Primary outcomes:
measure: Ability to isolate live bacteria from 95% of samples
timeFrame: 1-4 years
Secondary outcomes:
measure: Ability to measure quantitative Colony Forming Units (CFUs) in 90% of samples
timeFrame: 1-4 years
Other outcomes:
Locations:
Study officials:
affiliation: Stanford University
name: Sean P Spencer, MD,PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Stanford University
name: Linda A Nguyen, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04534166: A Model for Risk Prediction of Fracture in Diabetic Patients With Osteoporosis
Official title: A Model for Risk Prediction of Fracture in Diabetic Patients With Osteoporosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthcare; Risk Prediction; Diabetic Patients With Osteoporosis
Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2020-09-01
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chinese

Brief summary: The fracture risk of diabetic patients proves to be higher than those without diabetesdue to thehyperglycemia, usage of diabetes drugs, the changes in insulin levels and excretion, and this risk begins as early as adolescence.Many factors may be related to bone metabolism in patients with diabetes, including demographic data (e.g. age, height, weight, gender), medical history (e.g. smoking, drinking, menopause) and examination (e.g. bone mineral density, blood routine), urine routine).However, most of existing methods are qualitative assessments and do not take the interactions of the physiological factors of humans into consideration. In addition, the fracture risk of diabetic patients with osteoporosis has not been further studied before. In order to investigate the effect of patients' physiological factors on fracture risk, in the paper, we used a hybrid model combining XGBoost with deep neural network to predict the fracture risk of diabetic patients with osteoporosis.


Eligibility criteria: Inclusion Criteria:

* Patients in Hospital's outpatient and inpatient His database between July 2012 and November 2022, diabetic patients were combined with osteoporosis.

Exclusion Criteria:

* Patients with fractures before diagnosis of diabetes; patients with fractures before diagnosis of osteoporosis; patients with hyroid disease and other diseases that seriously affect bone metabolism.

Primary outcomes:
measure: Fracture
timeFrame: 2-10 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06408766: Investigating the Effects of Smartphone Use on the Masseter Muscle
Official title: Investigating the Short and Long-term Effects of Smartphone Use on the Masseter Muscle
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smartphone Addiction
Masseter Muscle Hypertrophy
Masseter Muscle Spasm
Keywords: Smartphone Addiction
masseter
thenar
Lead sponsor: Bandırma Onyedi Eylül University
Sponsor class: OTHER
First posted: 2024-05-10
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: University students

Brief summary: The aim of this study was to determine the short- and long-term effects of smartphone use on the masseter muscle. In the short term, to investigate whether repetitive thumb movements during phone use will cause a spontaneous muscle activation and/or tenderness in the masseter muscle; in the long term, to investigate the relationship between strength change and tenderness of the tenar and masseter muscles depending on the intensity and duration of phone use.

Detailed description: A total of 120 healthy university students aged 18-30 years at Bandırma Onyedi Eylül University will be included in our study. Descriptive data form, Smartphone Addiction Scale - Short Form, Edinburg Hand Preference Inventory, pressure pain threshold, muscle activity, lateral grip strength, hand grip strength will be evaluated in the participant students.

Eligibility criteria: Inclusion Criteria:

* Smartphone users students between the ages of 18-30 years
* Students whose voluntary informed consent was obtained

Exclusion Criteria:

* Individuals undergoing masseter botox application
* Individuals diagnosed with TMJ disorder and/or bruxism
* Individuals with musculoskeletal problems with evidence of a systemic, specific pathologic condition such as fracture of the hand, finger, upper extremity and/or TMJ, rheumatoid disease
* Individuals who have undergone any surgical operation related to hand, finger, upper extremity and/or TMJ problem
* Individuals with less than 6 months of physiotherapy and rehabilitation services related to hand, finger, upper extremity and/or TMJ
* Individuals with facial paralysis
* Individuals with diagnosed psychiatric illness.

Primary outcomes:
measure: Smartphone Addiction Scale-Short Form
timeFrame: 4 months
measure: Edinburg Hand Preference Inventory
timeFrame: 4 months
measure: Pressure Pain Threshold Assessment
timeFrame: 4 months
measure: Muscle Activation Measurement
timeFrame: 4 months
measure: Hand Grip Strength Assessment
timeFrame: 4 months
measure: Finger Lateral Grip Strength Assessment
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Balikesir
country: Turkey
facility: Bandirma Onyedi Eylul University
state: Bandirma
Study officials:
References:
Clinical trial NCT05280366: STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
Official title: A Prospective, Randomized, Multi-center Evaluation of the Safety and Effectiveness of the STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Open Angle Glaucoma
Keywords: glaucoma
Goniotomy
MIGS
Lead sponsor: New World Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2022-03-15
Enrollment: 150
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study of the Streamline Surgical System versus competitor


Eligibility criteria: Inclusion Criteria:

Diagnosis of Mild to Moderate Primary Open Angle Glaucomma

Exclusion Criteria:

* Other types of glaucoma including but not limited to: Normal tension glaucoma, pseudoexfoliative glaucoma, narrow angle glaucoma, traumatic, congenital, malignant, uveitic or neovascular glaucoma. Ocular hypertension.

Primary outcomes:
measure: Change in mean unmedicated diurnal Intraocular Pressure (IOP)
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Fayetteville
country: United States
facility: Vold Vision
state: Arkansas
city: Newport Beach
country: United States
facility: Visionary Research Institute
state: California
city: Torrance
country: United States
facility: Wolstan and Goldberg Eye Associates
state: California
city: Aurora
country: United States
facility: University of Colorado
state: Colorado
city: Ocala
country: United States
facility: Ocala Eye
state: Florida
city: Atlanta
country: United States
facility: Georgia Eye Partners
state: Georgia
city: Louisville
country: United States
facility: The Eye Institute
state: Kentucky
city: Saint Louis
country: United States
facility: Ophthalmology Associates
state: Missouri
city: Dover
country: United States
facility: Eye Associates of North New Jersey
state: New Jersey
city: Vineland
country: United States
facility: Eye Associates Surgical Center
state: New Jersey
city: Orchard Park
country: United States
facility: Ross Eye Institute
state: New York
city: Rapid City
country: United States
facility: Black Hills Regional Eye Institute
state: South Dakota
city: Maryville
country: United States
facility: University Eye Specialists
state: Tennessee
city: Fort Worth
country: United States
facility: Ophthalmology Associates
state: Texas
city: Houston
country: United States
facility: Berkely Eye Center
state: Texas
city: San Antonio
country: United States
facility: R & R Eye Research
state: Texas
city: Lynchburg
country: United States
facility: Piedmont Eye Center
state: Virginia
city: Racine
country: United States
facility: Eye Centers of Racine and Kenosha
state: Wisconsin
city: San José
country: Costa Rica
facility: Clinica 20/20
city: Puebla
country: Mexico
facility: Clinica Laser y Ultrasonido Ocular
Study officials:
affiliation: New World Medical, Inc.
name: Elysia Ison, OD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01882166: Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment
Official title: Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Infertility, Female
Keywords: Fertilization in Vitro
Sperm Injections, Intracytoplasmic
Follicle Stimulating Hormone
Embryonic Development
Lead sponsor: St. Olavs Hospital
Sponsor class: OTHER
First posted: 2013-06-20
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The number of children conceived by assisted reproductive technology is increasing in Nordic countries as well as worldwide. An important factor of success in treatment of infertility is a short "time to pregnancy" with impact on both economical aspects for the society and medical and psychological aspects for the couple. During treatment, success relies on 1) optimal stimulation of growth and maturation of multiple follicles by administration of exogenous follicle stimulating hormone (FSH), and 2) selection of the fertilized egg / embryo with the highest potential of implantation to be transferred to the mother. In the present project stimulation of egg production by human urine derived FSH (Fostimon®) and recombinant FSH (Puregon®) will be compared. To this end early embryo development and kinetics after fertilization will be evaluated. The system to be used is time-lapse recording of embryo morphology during the first days of embryo development by means of an embryoscope. Aim of this study is to investigate if Puregon and urinary Fostimon have different effect on embryo quality. The hypothesis of the study is that stimulation of egg production by these two types of follicle stimulating hormone does not have the same effect on early embryo quality.


Eligibility criteria: Inclusion Criteria:

* First or second intracytoplasmic sperm injection (ICSI) treatment
* BMI 18-32 kg/m²
* No previous ovarian hyperstimulation syndrome (OHSS)
* Regular menstrual cycle (cycle length 28 ± 3 days
* Less than 20 antral follicles evaluated by vaginal ultrasound
* S- Anti-Müller Hormone (AMH) 10 - 40 pmol/L
* has given informed consent

Primary outcomes:
measure: Embryo quality
timeFrame: 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: IVF Unit, St. Olavs Hospital
Study officials:
affiliation: St. Olavs Hospital
name: Arne Sunde, phd
role: STUDY_CHAIR
References:
Clinical trial NCT02473666: Patient Blood Management - Use and Outcome
Official title: Patient Blood Management - Use and Outcome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemorrhage
Keywords: Patient Blood Management
Red Blood Cells
Platelet
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2015-06-16
Enrollment: 250000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All cases of all in hospital patients. Area of Focus: Transfusions of blood products.

Brief summary: Study the influence of transfusion related Patient Blood Management Program actions on transfusion-related outcome measures and cost.

Detailed description: At the University Hospital of Zurich, an in-house designed monitoring and feedback system was introduced which electronically registers each transfusion of any allogeneic blood product, be it red blood cells, plasma or platelets as well as corresponding laboratory data. Results are reported quarterly to Department heads. The investigator analyzes whether the introduction of this monitoring and feedback system as part of a patient blood management Program has a significant influence on use of allogeneic blood product transfusions and transfusion-related costs, without compromising patient outcome.

Eligibility criteria: Inclusion Criteria:

* Only case records, all discharged patients of the University Hospital of Zürich

Exclusion Criteria:

* Not discharged from our Hospital.

Primary outcomes:
measure: Percentage of transfusions per participant
timeFrame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Secondary outcomes:
measure: Percentage of transfusion of any blood product per participant
timeFrame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
measure: Cost of any blood product per participant
timeFrame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
measure: Survey of Patient Blood Management System
timeFrame: participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich
Study officials:
affiliation: IFA University Hospital Zurich
name: Donat R Spahn, Prof
role: PRINCIPAL_INVESTIGATOR
References: